Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
AstraZeneca
Moodys
Merck
Johnson and Johnson

Last Updated: January 28, 2022

DrugPatentWatch Database Preview

ZYPITAMAG Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Zypitamag, and when can generic versions of Zypitamag launch?

Zypitamag is a drug marketed by Medicure and is included in one NDA. There is one patent protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in ZYPITAMAG is pitavastatin magnesium. There are fifteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the pitavastatin magnesium profile page.

DrugPatentWatch® Generic Entry Outlook for Zypitamag

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 19, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for ZYPITAMAG
Drug patent expirations by year for ZYPITAMAG
Drug Prices for ZYPITAMAG

See drug prices for ZYPITAMAG

DrugPatentWatch® Estimated Generic Entry Opportunity Date for ZYPITAMAG
Generic Entry Date for ZYPITAMAG*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ZYPITAMAG

US Patents and Regulatory Information for ZYPITAMAG

ZYPITAMAG is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZYPITAMAG is ⤷  Sign up for a Free Trial.

This potential generic entry date is based on patent ⤷  Sign up for a Free Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ZYPITAMAG

Method for preparation of pitavastatin and pharmaceutical acceptable salts thereof
Patent Number: ⤷  Sign up for a Free Trial
Patent Expiration: ⤷  Sign up for a Free Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Medicure ZYPITAMAG pitavastatin magnesium TABLET;ORAL 208379-001 Jul 14, 2017 DISCN Yes No ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial Y Y ⤷  Sign up for a Free Trial
Medicure ZYPITAMAG pitavastatin magnesium TABLET;ORAL 208379-002 Jul 14, 2017 RX Yes No ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial Y Y ⤷  Sign up for a Free Trial
Medicure ZYPITAMAG pitavastatin magnesium TABLET;ORAL 208379-003 Jul 14, 2017 RX Yes Yes ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial Y Y ⤷  Sign up for a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Mallinckrodt
Colorcon
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.